Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Gastroenterology

Expert Opinion / Commentary · April 27, 2016

What's With the Bad Publicity for Anti-Reflux Surgery?

Written by
Steven R. DeMeester MD


Additional Info

  1. Khan F, Maradey-Romero C, Ganocy S, et al. Utilization of surgical fundoplication for patients with gastro-oesophageal reflux disease in the USA has declined rapidly between 2009 and 2013 [published online April 6, 2016]. Aliment Pharmacol Ther. DOI: 10.1111/apt.13611.
  2. Boeckxstaens G, El-Serag HB, Smout AJ, Kahrilas PJ. Symptomatic reflux disease: the present, the past and the future. Gut. 2014;63(7):1185-1193.
  3. Lundell L, Miettinen P, Myrvold H, et al. Continued (5 years) follow-up of a randomised clinical study comparing anti-reflux surgery and omeprazole in gastroesophageal reflux surgery. J Am Coll Surg. 2001;192(2):172-179; discussion 179-181.
  4. Galmiche J-P, Hatlebakk J, Attwood S, et al. Laparoscopic antireflux surgery vs esomeprazole treatment for chronic GERD: the LOTUS randomized clinical trial. JAMA. 2011; 305(19):1969-1977.
  5. Spechler S, Lee E, Ahnen D, et al. Long-term Outcome of Medical and Surgical Therapies for Gastroesophageal Reflux Disease: Follow-up of a Randomized Controlled Trial. JAMA. 2001;2855(18):2331-2338
  6. Lundell L, Miettinen P, Myrvold HE, et al. Comparison of outcomes twelve years after antireflux surgery or omeprazole maintenance therapy for reflux esophagitis. Clin Gastroenterol Hepatol. 2009;7(12):1292-1298.
  7. Shah NH, LePendu P, Bauer-Mehren A, et al. Proton Pump Inhibitor Usage and the Risk of Myocardial Infarction in the General Population. PLoS ONE. 2015;10(6):e0124653.
  8. Maret-Ouda J, Konings P, Lagergren J, Brusselaers N. Antireflux Surgery and Risk of Esophageal Adenocarcinoma: A Systematic Review and Meta-analysis. Ann Surg. 2016;263(2):251-257.
  9. Dallemagne B, Weerts J, Markiewicz S, et al. Clinical results of laparoscopic fundoplication at ten years after surgery. Surg Endosc. 2006;20(1):159-165.
  10. Robinson B, Dunst C, Cassera M, et al. 20 years later: Laparoscopic fundoplication durability. Surg Endosc. 2015;29(9):2520-2524.
  11. Lord RV, Kaminski A, Oberg S, et al. Absence of gastroesophageal reflux disease in a majority of patients taking acid suppression medications after Nissen fundoplication. J Gastrointest Surg. 2002;6(1):3-9; discussion 10.

  12. Campos GM, Peters JH, DeMeester TR, et al. Multivariate analysis of factors predicting outcome after laparoscopic Nissen fundoplication. J Gastrointest Surg. 1999;3(3):292-300.

  13. Bytzer P. What makes individuals with gastroesophageal reflux disease dissatisfied with their treatment? Clin Gastroenterol Hepatol. 2009;7(8):816-822.
  14. Chey WD, Mody RR, Izat E. Patient and physician satisfaction with proton pump inhibitors (PPIs): are there opportunities for improvement? Dig Dis Sci. 2010;55(12):3415-3422.
  15. Streets C, DeMeester SR, DeMeester TR, et al. Excellent quality of life after Nissen fundoplication depends on successful elimination of reflux symptoms and not the invasiveness of the surgical approach. Ann Thorac Surg. 2002;74(4):1019-1025.

  16. Peters JH, DeMeester TR, Crookes P, et al. The treatment of gastroesophageal reflux disease with laparoscopic Nissen fundoplication: prospective evaluation of 100 patients with "typical" symptoms. Ann Surg. 1998;228(1):40-50.
  17. Lord RV, DeMeester SR, JH Peters, et al. Hiatal hernia, lower esophageal sphincter incompetence, and effectiveness of Nissen fundoplication in the spectrum of gastroesophageal reflux disease. J Gastrointest Surg. 2009;13(4):602-610.
  18. Oberg S, DeMeester TR, Peters JH, et al. The extent of Barrett's esophagus depends on the status of the lower esophageal sphincter and the degree of esophageal acid exposure. J Thorac Cardiovasc Surg. 1999;117(3):572-580.

  19. Labenz J, Jaspersen D, Kulig M, et al. Risk factors for erosive esophagitis: a multivariate analysis based on the ProGERD study initiative. Am J Gastro. 2004;99(9):1652-1656.
  20. El-Serag HB, Johanson JF. Risk factors for the severity of erosive esophagitis in Helicobacter pylori-negative patients with gastroesophageal reflux disease. Scand J Gastroenterol. 2002;37(8):899-904.

  21. Malfertheiner P, Nocon M, Vieth M, et al. Evolution of gastro-oesophageal reflux disease over 5 years under routine medical care--the ProGERD study. Alimen Pharm Therapeutics. 2012;35(1):154-164.
  22. Bonavina L, Evander A, DeMeester TR, et al. Length of the distal esophageal sphincter and competency of the cardia. Am J Surg. 1986;151(1):25-34.

  23. Chandrasoma P. Pathological basis of gastroesophageal reflux disease. World J Surg. 2003;27(9):986-993.

Disclosure statements are available on the authors' profiles:

Further Reading